Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 4Phase 3 3Phase 1/2 3Phase 2/3 1

Status

Recruiting 3Completed 3Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 2Colorectal Neoplasms 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Cisplatin 111Carboplatin 111pembrolizumab 109Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × folfirinox × Clear all
NCT03828799 2026-02-27

FOLFIRINOX-R

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 1/2 Completed
13 enrolled 22 charts
Gastrointestinal

Colorectal Neoplasms

NCT04431258 2024-03-18

PanC-ASAP

Ability Pharmaceuticals SL

Phase 1/2 Completed
150 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT01488552 2016-08-18

Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

Pancreatic Cancer Research Team

Phase 1/2 Completed
60 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡